Earnings Feed
Start Free
|4Apr 6, 12:56 PM ET

GENZYME CORP 4

4 · GENZYME CORP · Filed Apr 6, 2011

Insider Transaction Report

Form 4
Period: 2011-04-04
GENZYME CORPGENZ
SYRON RICHARD F/CA
Director
Transactions
  • Disposition to Issuer

    Genzyme common stock (GENZ)

    2011-04-04$74.00/sh−2,375$175,750→ 5,011 total
  • Disposition from Tender

    Genzyme common stock (GENZ)

    2011-04-04$74.00/sh−5,011$370,814→ 0 total
  • Exercise/Conversion

    Restricted Stock Units

    2011-04-04−2,375→ 0 total
    Exercise: $0.00→ Genzyme common stock (GENZ) (2,375 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$68.48/sh−7,500$513,600→ 0 total
    Exercise: $68.48From: 2009-05-22Exp: 2018-05-22→ Genzyme common stock (GENZ) (7,500 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$62.16/sh−15,000$932,400→ 0 total
    Exercise: $62.16From: 2008-05-24Exp: 2017-05-24→ Genzyme common stock (GENZ) (15,000 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$58.50/sh−15,000$877,500→ 0 total
    Exercise: $58.50From: 2007-05-25Exp: 2016-05-26→ Genzyme common stock (GENZ) (15,000 underlying)
  • Exercise/Conversion

    Genzyme common stock (GENZ)

    2011-04-04+2,375→ 7,386 total
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$51.52/sh−7,125$367,080→ 0 total
    Exercise: $51.52Exp: 2020-06-16→ Genzyme common stock (GENZ) (7,125 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$58.66/sh−7,500$439,950→ 0 total
    Exercise: $58.66From: 2010-05-21Exp: 2019-05-21→ Genzyme common stock (GENZ) (7,500 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$69.34/sh−15,000$1,040,100→ 0 total
    Exercise: $69.34From: 2006-05-25Exp: 2016-02-28→ Genzyme common stock (GENZ) (15,000 underlying)
Footnotes (2)
  • [F1]The vested restricted stock units were scheduled to vest on the date of the 2011 annual meeting of shareholders.
  • [F2]This option, which provided for vesting at the next annual meeting of shareholders, was cancelled upon the consummation of the sanofi-aventis tender offer in exchange for a payment representing (A) an amount of cash equal to the excess of $74.00 over the exercise price of the option, multiplied by the total number of shares subject to such options, and (B) one contingent value right (CVR) per cancelled option.

Documents

1 file
  • 4
    doc4.xmlPrimary